胰高血糖素样肽-1受体激动剂与葡萄膜炎风险
这项回顾性队列研究利用2006至2025年TriNetX美国协作网络的电子健康记录数据,纳入516 052例患者并按倾向评分匹配,评估处方GLP-1RA与葡萄膜炎风险的关系。结果显示GLP-1RA组葡萄膜炎风险低于对照组(RR 0.48,95%CI 0.46-0.51),在2型糖尿病患者和无糖尿病患者中结果一致。与二甲双胍和胰岛素相比,GLP-1RA处方与更强的葡萄膜炎保护相关,但与SGLT2i相比葡萄膜炎风险略有增加(RR 1.17,95%CI 1.04-1.32)。
要点
- GLP-1RA组葡萄膜炎风险低于对照组(RR 0.48,95%CI 0.46-0.51)。
- 2型糖尿病患者中RR 0.54(95%CI 0.51-0.58),无糖尿病患者中RR 0.52(95%CI 0.46-0.59)。
- 与SGLT2i相比,GLP-1RA与葡萄膜炎风险略有增加相关(RR 1.17,95%CI 1.04-1.32)。
核心结论
- 该队列研究发现,与对照组相比,处方GLP-1RA与较低的葡萄膜炎风险相关。
- 这些发现提示GLP-1RA可能具有超越血糖控制的抗炎获益,需进一步研究其在眼部炎症性疾病中的作用。
研究设计与样本
- 这是一项回顾性队列研究,使用2006至2025年电子健康记录网络数据。
- 数据来自TriNetX美国协作网络这一大型多中心电子健康记录平台。
- 采用倾向评分匹配控制人口学特征、吸烟状态、高血压、体重指数、糖化血红蛋白和糖尿病视网膜病变分期。
- 纳入有或无糖尿病且处方GLP-1RA、二甲双胍、胰岛素或SGLT2i的患者,对照组为未处方相应药物的患者。
- 共纳入516 052例患者,GLP-1RA组258 026例(平均[SD]年龄56.4[13.7]岁;女性159 025例[61.6%]),对照组258 026例(平均[SD]年龄56.4[14.0]岁;女性159 374例[61.8%])。
主要发现
- GLP-1RA组葡萄膜炎风险低于对照组(RR 0.48;95%CI 0.46-0.51)。
- 2型糖尿病患者中GLP-1RA组葡萄膜炎风险低于对照组(RR 0.54;95%CI 0.51-0.58)。
- 无糖尿病患者中GLP-1RA组葡萄膜炎风险低于对照组(RR 0.52;95%CI 0.46-0.59)。
- 与二甲双胍组相比,GLP-1RA处方与更强的葡萄膜炎保护相关(RR 0.58;95%CI 0.54-0.62)。
- 与胰岛素组相比,GLP-1RA处方与更强的葡萄膜炎保护相关(RR 0.57;95%CI 0.54-0.61)。
关键数值与推荐
- 主要结局为非感染性葡萄膜炎的发病率,通过国际疾病分类(ICD)就诊诊断代码识别。
- 分析包括总体葡萄膜炎风险及亚型如脉络膜视网膜炎症、前葡萄膜炎、全葡萄膜炎和视网膜血管炎。
- 计算风险比(RR)及95%CI以评估GLP-1RA使用与葡萄膜炎风险的关联。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Emerging evidence suggests that glucagon-like peptide-1 receptor agonists (GLP-1RAs), commonly used for glycemic control in diabetes, may possess anti-inflammatory properties. Understanding their potential protective role against uveitis could provide insights into novel therapeutic strategies. OBJECTIVE: To evaluate whether being prescribed a GLP-1RA is associated with a reduced risk of developing uveitis. DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective cohort study using electronic health record (EHR) network data from 2006 to 2025. Propensity score matching was applied to control for demographics, smoking status, hypertension, body mass index, hemoglobin A1c, and diabetic retinopathy stage. Data from the US Collaborative Network of TriNetX, a large multicenter EHR platform, were used in this analysis. Included were patients with and without diabetes with prescriptions for GLP-1RAs, metformin, insulin, or sodium-glucose cotransporter 2 inhibitors (SGLT2is). The control groups consisted of patients without prescriptions for each medication. EXPOSURE: Use of GLP-1RAs, metformin, insulin, or SGLT2is, identified through prescription records. MAIN OUTCOMES AND MEASURES: The primary outcome was the incidence of noninfectious uveitis, identified using International Classification of Diseases (ICD) encounter diagnosis codes. Risk ratios (RRs) with 95% CIs were calculated to assess the association between GLP-1RA use and uveitis risk. Analyses included risk of overall uveitis and subtypes such as chorioretinal inflammation, anterior uveitis, panuveitis, and retinal vasculitis. RESULTS: A total of 516 052 patients were included in this study, 258 026 (mean [SD] age, 56.4 [13.7] years; 159 025 female [61.6%]) in the GLP-1RA group and 258 026 (mean [SD] age, 56.4 [14.0] years; 159 374 female [61.8%]) in the control group. The GLP-1RA cohort had a reduced risk of uveitis compared with controls (RR, 0.48; 95% CI, 0.46-0.51). This was consistent among those with type 2 diabetes (RR, 0.54; 95% CI, 0.51-0.58) and those without diabetes (RR, 0.52; 95% CI, 0.46-0.59). Compared with the cohorts taking metformin (RR, 0.58; 95% CI, 0.54-0.62) and insulin (RR, 0.57; 95% CI, 0.54-0.61), GLP-1RA prescriptions were associated with greater protection against uveitis. However, GLP-1RAs were associated with a slightly increased uveitis risk vs SGLT2is (RR, 1.17; 95% CI, 1.04-1.32). SGLT2i prescriptions were also associated with reduced uveitis risk compared with controls (RR, 0.52; 95% CI, 0.48-0.56). CONCLUSIONS AND RELEVANCE: This cohort study found that GLP-1RA prescriptions were associated with a lower risk of uveitis compared with controls. These findings suggest potential anti-inflammatory benefits beyond glycemic control, warranting further investigation into their role in ocular inflammatory diseases.
引用
- Mohan N, Srivastava SK, Schulgit MJ, et al. Glucagon-Like Peptide-1 Receptor Agonists and Risk of Uveitis. JAMA Ophthalmol. 2025. PMID: 40875223. doi:10.1001/jamaophthalmol.2025.2822
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。